Form 4: Nuvation Bio CTO Exercises Options, Sells Shares

Nuvation Bio's Chief Technical Operations, David C. Hanley, exercised stock options and subsequently sold 200,000 Class A Common Stock shares.

Summary

• David C. Hanley, Chief Technical Operations of Nuvation Bio Inc. (NUVB), executed a series of transactions on November 19, 2025.
• Hanley exercised stock options to acquire 200,000 shares of Class A Common Stock at an exercise price of $1.87 per share.
• Immediately following the option exercise, Hanley sold 200,000 shares of Class A Common Stock at a weighted-average price of $7.1384 per share, with individual sales ranging from $7.045 to $7.260.
• The transactions were made pursuant to a Rule 10b5-1 pre-planned trading arrangement.
• Following these transactions, Hanley directly owns 24,000 shares of Class A Common Stock and 300,000 stock options.
• The reported beneficial ownership of 224,000 shares after the acquisition transaction includes 3,000 shares acquired on May 19, 2025, and 3,000 shares acquired on November 19, 2025, under the Issuer's 2021 Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The transaction is a routine insider exercise and sale, pre-planned under a 10b5-1 plan. While insider selling can sometimes be viewed negatively, the pre-planned nature mitigates concerns about opportunistic selling. The executive realized a significant profit, which is positive for the individual but neutral to slightly negative for market sentiment if not fully understood as routine.

Positives

• The Chief Technical Operations exercised options at a low price ($1.87) and sold shares at a significantly higher price ($7.1384), indicating a profitable transaction for the insider.
• The transaction was executed under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not based on new, non-public information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market, as it reduces the insider's direct equity stake.

Future Outlook

NA

Industry Context

This filing reflects routine insider compensation and liquidity management within the biotechnology or pharmaceutical industry, where stock options are a common component of executive compensation. The exercise and sale of options are standard practices for executives to realize value from their equity awards.

Related Party Transactions

• The transactions involve David C. Hanley, the Chief Technical Operations of Nuvation Bio Inc., making them related party transactions. These are standard compensation-related dealings.

Stakeholder Impact

• Shareholders: The sale of 200,000 shares by a key executive could be perceived as a slight negative, but the pre-planned nature under Rule 10b5-1 mitigates concerns about a lack of confidence in the company. It represents a routine liquidity event for the executive.
• Management: The transaction allows the Chief Technical Operations to realize value from his equity compensation.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction where an executive exercised options and sold shares for personal liquidity. It does not provide new fundamental information about Nuvation Bio's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transaction is expected and does not signal a significant shift in company prospects. Therefore, a "hold" recommendation is appropriate, as the filing itself does not present a compelling reason to buy or sell based solely on this information.

Keywords

Nuvation Bio, NUVB, insider trading, Form 4, stock options, equity sale, David C. Hanley, Chief Technical Operations, 10b5-1 plan, Class A Common Stock, employee stock purchase plan